Literature DB >> 21756890

Anti-centromere antibodies in a large cohort of systemic sclerosis patients: comparison between immunofluorescence, CENP-A and CENP-B ELISA.

Michael Mahler1, Daniel You, Murray Baron, Suzanne S Taillefer, Marie Hudson, Marvin J Fritzler.   

Abstract

INTRODUCTION: Anti-centromere antibodies (ACA) are useful biomarkers in the diagnosis of systemic sclerosis (SSc) where they are found in 20-40% of patients and, albeit with lower prevalence, in patients with other systemic autoimmune rheumatic diseases. Historically, ACA were detected by indirect immunofluorescence (IIF) on HEp-2 cells and confirmed by immunoassays using recombinant CENP-B. During the last few years, to accommodate high throughput diagnostics, a number of laboratories changed from IIF to ELISA assays. The objective of this study was to compare the detection of ACA by IIF to CENP-A and a CENP-B ELISA in a large cohort of SSc patients.
METHODS: Sera collected from SSc patients (n=834) were tested for ACA by IIF on HEp-2 cells (ImmunoConcepts, Sacramento, CA) and CENP-A and CENP-B ELISA (both Dr. Fooke Laboratorien GmbH, Neuss, Germany). Furthermore, other autoantibodies were determined by QUANTA-Plex(TM) SLE 8 profile (INOVA, San Diego, CA), QUANTA Lite RNA Pol III (INOVA) and PM1-Alpha ELISA (Dr. Fooke).
RESULTS: The prevalence of ACA was 35.0% by IIF, 41.6% by CENP-A and 57.8% by CENP-B ELISA. When the CENP-A and the CENP-B ELISA results were compared to the IIF, the area under the curve value derived from receiver operating characteristic analysis was 0.98 for both assays. ACA and anti-topoisomerase I antibodies co-occurred in 1.2% (ACA by IIF), in 3.5% (by CENP-A ELISA) and in 7.4% (by CENP-B ELISA). Anti-CENP-A antibodies were negatively associated with anti-Scl-70, anti-RNA Pol III, (both p<0.0001), anti-U1-RNP (p=0.008) and anti-PM1-Alpha antibodies (p=0.0337). The degree of association was dependent on the cut-off value used.
CONCLUSION: Although we found good agreement between IIF and ELISA for the detection of ACA in SSc, a significant portion of CENP ELISA positive sera did not show the typical ACA staining pattern. Based on these findings, we conclude that an IIF ACA negative result might not rule out the presence of ACA. In addition, new CENP ELISA kits are reliable for the detection of anti-CENP in SSc sera.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21756890     DOI: 10.1016/j.cca.2011.06.041

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  11 in total

1.  Association of Anticentromere Antibodies With More Severe Exocrine Glandular Dysfunction in Sjögren's Syndrome: Analysis of the Sjögren's International Collaborative Clinical Alliance Cohort.

Authors:  Alan N Baer; Leah Medrano; Mara McAdams-DeMarco; Thomas J Gniadek
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-09-16       Impact factor: 4.794

2.  A cross-sectional study of autoantibody profiles in the Waikato systemic sclerosis cohort, New Zealand.

Authors:  Winston S J Chang; Joanna Schollum; Douglas H N White; Kamal K Solanki
Journal:  Clin Rheumatol       Date:  2015-05-29       Impact factor: 2.980

3.  Comparing Genomic Profiles of Women With and Without Fibromyalgia.

Authors:  Nada Lukkahatai; Brian Walitt; Alexandra Espina; Dan Wang; Leorey N Saligan
Journal:  Biol Res Nurs       Date:  2015-05-26       Impact factor: 2.522

4.  Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis.

Authors:  Marie Hudson; Janet Pope; Michael Mahler; Solène Tatibouet; Russell Steele; Murray Baron; Marvin J Fritzler
Journal:  Arthritis Res Ther       Date:  2012-03-06       Impact factor: 5.156

Review 5.  Coherent somatic mutation in autoimmune disease.

Authors:  Kenneth Andrew Ross
Journal:  PLoS One       Date:  2014-07-02       Impact factor: 3.240

Review 6.  Guarding the Genome: CENP-A-Chromatin in Health and Cancer.

Authors:  Megan A Mahlke; Yael Nechemia-Arbely
Journal:  Genes (Basel)       Date:  2020-07-16       Impact factor: 4.096

7.  Increased Autoantibodies Against Ro/SS-A, CENP-B, and La/SS-B in Patients With Kidney Allograft Antibody-mediated Rejection.

Authors:  Sergi Clotet-Freixas; Max Kotlyar; Caitriona M McEvoy; Chiara Pastrello; Sonia Rodríguez-Ramírez; Sofia Farkona; Heloise Cardinal; Mélanie Dieudé; Marie-Josée Hébert; Yanhong Li; Olusegun Famure; Peixuen Chen; S Joseph Kim; Emilie Chan; Igor Jurisica; Rohan John; Andrzej Chruscinski; Ana Konvalinka
Journal:  Transplant Direct       Date:  2021-09-20

8.  Positioning of myositis-specific and associated autoantibody (MSA/MAA) testing in disease criteria and routine diagnostic work-up.

Authors:  Carolien Bonroy; Yves Piette; Yves Allenbach; Xavier Bossuyt; Jan Damoiseaux
Journal:  J Transl Autoimmun       Date:  2022-02-11

9.  Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease.

Authors:  Federico Perosa; Elvira Favoino; Isabella Eleonora Favia; Serena Vettori; Marcella Prete; Addolorata Corrado; Francesco Paolo Cantatore; Gabriele Valentini
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

Review 10.  Next-Generation Autoantibody Testing by Combination of Screening and Confirmation-the CytoBead® Technology.

Authors:  Mandy Sowa; Rico Hiemann; Peter Schierack; Dirk Reinhold; Karsten Conrad; Dirk Roggenbuck
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.